CpG ODN with immune regulation function and application thereof
Provided are a chemically modified immunomodulatory CpG ODN having a structure represented by general formula I and an application thereof, the CpG ODN having immunostimulatory activity, being capable of stimulating B cell proliferation, and generating specific cytokines at the same time. The CpG ODN can be independently used as a vaccine adjuvant, can also be combined with other adjuvants to play a synergistic role, and can also be applied to preparation of drugs for preventing or treating tumors, infection and allergy..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Europäisches Patentamt - (2022) vom: 29. Nov. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
WANG LIGONG [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-29, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 |
---|
Patentnummer: |
CN115413298 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA002885891 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | EPA002885891 | ||
003 | DE-627 | ||
005 | 20240409142249.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240409s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA002885891 | ||
035 | |a (EPA)CN115413298 | ||
035 | |a (EPA)77929639 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a WANG LIGONG |e verfasserin |4 aut | |
245 | 1 | 0 | |a CpG ODN with immune regulation function and application thereof |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-29, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09 | ||
520 | |a Provided are a chemically modified immunomodulatory CpG ODN having a structure represented by general formula I and an application thereof, the CpG ODN having immunostimulatory activity, being capable of stimulating B cell proliferation, and generating specific cytokines at the same time. The CpG ODN can be independently used as a vaccine adjuvant, can also be combined with other adjuvants to play a synergistic role, and can also be applied to preparation of drugs for preventing or treating tumors, infection and allergy. | ||
650 | 4 | |a bio | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a SHAO YAN |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 29. Nov. |
773 | 1 | 8 | |g year:2022 |g day:29 |g month:11 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/77929639/publication/CN115413298A1?q=CN115413298 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2022 |b 29 |c 11 |